these products are prepared by condensation , in a solvent such as methanol , of the cyanamide monosodium derivative on the corresponding n - substituted 1 - amino - 2 , 3 - epoxypropane ## str4 ## the epoxides are prepared in the standard way by reaction of an amine hnr 1 r 2 ( in which r 1 and r 2 are defined above ) and epichlorohydrin . the invention will be further illustrated by certain examples and references which are provided for purposes of illustration only and are not intended to limit the present invention . preparation of 2 - amino - n , n - 5 - diethylaminomethyl - 2 - oxazoline . formula i with r 1 = r 2 = c 2 h 5 . one mole of diethylamine is introduced in a reactor equipped with stirring , cooling and a dropping funnel . one mole of epichlorohydrin is introduced , drop by drop , with stirring , while the temperature is kept at 25 ° c . the stirring is contiued for 5 hours at ambient temperature . ether ( 300 cc ) is added to the reactor then 48 g of finely powdered soda . the stirring is continued overnight at ambient temperature . the ether phase is filtered and centrifuged . it is washed with 50 cc of water . after decanting , the organic phase is carefully dried on sodium sulfate . the solvent is eliminated under lower pressure and the 1 - diethylamino - 2 , 3 - epoxypropane is separated by distillation . yield : 60 %, bp 8 = 44 °- 48 ° c ., bp 760 = 157 ° c . 0 . 2 mole of the 1 - diethylamino - 2 , 3 - epoxypropane thus prepared is added , drop by drop , to 12 . 8 g of the cyanamide monosodium derivative dissolved in 200 cc of anhydrous methanol with vigorous stirring . after 15 hours of stirring at ambient temperature , the methanol is evaporated and the residue picked up with 300 cc of ether . the precipitate is eliminated by filtering . the ether phase is washed twice with 2 cc of water then dried on na 2 so 4 after decanting . the ether is evaporated under low pressure . the resulting oily phase crystallizes after washing with boiling heptane . 2 - amino - 5 - diethylaminomethyl - 2 - oxazoline is thus obtained with a yield of 68 %. it is purified by recrystallization in heptane . infrared spectrum : bands γnh 2 3360 cm - 1 , γc ═ n 1680 cm - 1 . the nmr of the proton in dmso ( d 6 ) ( the chemical shifts are expressed in ppm in relation to the tms taken as the internal standard ): 5 . 78 ppm , singlet , 2 protons ( nh 2 ); 4 . 67 - 4 . 29 ppm , complex mass , 1 proton ( h - 5 on the oxazoline ring ); 3 . 78 - 3 . 05 ppm , complex mass , 2 protons ( h in 4 on the oxazoline ring ); 2 . 71 - 2 . 31 ppm , complex mass , 6 protons ( n -- ch 2 ); 0 . 93 ppm , triplet , 6 protons ( ch 3 --). synthesis of 2 - amino - 5 -( n - butyl - n - methylaminomethyl )- 2 - oxazoline . formula i with r 1 = ch 3 , r 2 = c 4 h 9 . this product is prepared according to the method described in example 1 . the intermediate product has a boiling point of 44 °- 50 ° c . under 0 . 5 mm of hg . the final product is purified by recrystallation in hexane . infrared spectrum : bands γnh 2 3280 cm - 1 , γc ═ n 1680 cm - 1 . nmr spectrum in dmso ( d 6 ): 5 . 8 ppm , singlet , 2 protons ( nh 2 ); 4 . 71 - 4 . 33 ppm , complex mass , 1 proton ( h in 5 of the oxazoline ring ); 3 . 78 - 3 ppm , complex mass , 2 protons ( h in 4 of the oxazoline ring ); 2 . 62 - 2 . 1 ppm , complex mass , 7 protons ## str5 ## 1 . 55 - 1 . 05 ppm , complex mass , 4 protons ( c -- ch 2 -- ch 2 -- c ); 1 - 0 . 71 ppm , complex mass , 3 protons ( ch 3 -- c ). synthesis of 2 - amino - 5 - pyrrolidinomethyl - 2 - oxazoline . formula i with r 1 , r 2 =-- ch 2 -- ch 2 -- ch 2 -- ch 2 --. this product is prepared by the method described in example 1 with the sole difference that the addition reaction of pyrrolidine and epichlorohydrin is performed in the presence of ether . the intermediate eposide has a boiling point of 73 ° c . under 25 mm of hg . the 2 - amino - 5 - pyrrolidinomethyl - 2 - oxazoline is purified by recrystallization in heptane . infrared spectrum : bands γnh 2 3300 cm - 1 , γc ═ n 1685 cm - 1 , nmr spectrum in dmso ( d 6 ): 5 . 82 ppm , singlet , 2 protons ( nh 2 ); 4 . 71 - 4 . 29 ppm , complex mass , 1 proton ( h in 5 of the oxazoline ring ); 3 . 78 - 3 . 02 ppm , complex mass , 2 protons ( h in 4 of the oxazoline ring ); 2 . 66 - 2 . 31 ppm , complex mass , 6 protons ( ch 2 -- n ); 1 . 87 - 1 . 44 ppm , complex mass , 4 protons ( ch 2 -- c ). synthesis of 2 - amino - 5 - piperidinomethyl - 2 - oxazoline . formula i with r 1 , r 2 = ch 2 -- ch 2 -- ch 2 -- ch 2 -- ch 2 --. this product is prepared by the method described in example 1 . the intermediate epoxide has a boiling point of 51 ° c . under 0 . 5 mm of hg . the final product is purified by recrystallization in heptane . infrared spectrum : bands γnh 2 3350 cm - 1 , γc ═ n 1680 cm - 1 . nmr spectrum in dmso ( d 6 ): 5 . 8 ppm , singlet , 2 protons ( nh 2 ); 4 . 77 - 4 . 35 ppm , complex mass , 1 proton ( h in 5 of oxazoline ring ); 3 . 77 - 2 . 95 ppm , complex mass , 2 protons ( h in 4 of oxazoline ring ); 2 . 58 - 216 ppm , complex mass , 6 protons ( ch 2 -- n ); 1 . 64 - 1 . 2 ppm , complex mass , 6 protons ( ch 2 -- c ). synthesis of 2 - amino - 5 -( 4 - methylpiperidinomethyl )- 2 - oxazoline . formula i with r 1 , r 2 = ## str6 ## this product is synthesized by the method described in example 1 . the intermediate epoxide has a boiling point of 55 ° c . under 0 . 5 mm of hg . the final product is recrystallized in heptane . infrared spectrum : bands γnh 2 3260 cm - 1 , γc ═ n 1690 cm - 1 . nmr spectrum in dmso ( d 6 ): 5 . 82 ppm , singlet , 2 protons ( nh 2 ); 4 . 78 - 4 . 33 ppm , complex mass , 1 proton ( h in 5 of the oxazoline ring ); 3 . 78 - 3 ppm , complex mass , 2 protons ( h in 4 of the oxazoline ring ); 3 . 0 - 9 ppm , complex mass , 11 protons ( ch 2 -- n + h of piperidine ring ); 0 . 87 ppm , doublet , 3 protons ( ch 3 ). synthesis of 2 - amino - 5 -( 2 - ethylpiperidinomethyl )- 2 - oxazoline . formula i with r 1 , r 2 = ## str7 ## this product is synthesized by the method described in example 1 . the intermediate epoxide has a boiling point of 83 ° c . under 0 . 5 mm of hg . the final product is recrystallized in heptane . infrared spectrum : bands γnh 2 3350 cm - 1 , γc ═ n 1680 cm - 1 . nmr spectrum in dmso ( d 6 ): 5 . 82 ppm , singlet , 2 protons ( nh 2 ); 4 . 75 - 4 . 33 ppm , complex mass , 1 proton ( h in 4 of the oxazoline ring ); 3 - 2 . 05 ppm , complex mass , 5 protons ( ch 2 -- n + ch -- n ); 1 . 77 - 1 . 11 ppm , complex mass , 8 protons ( ch 2 -- c ); 0 . 8 ppm , triplet , 3 protons ( ch 3 ). synthesis of 2 - amino - 5 - morpholinomethyl - 2 - oxazoline . formula i with r 1 , r 2 = ch 2 -- ch 2 -- o -- ch 2 -- ch 2 --. this product is synthesized by the method described in example 1 . the intermediate epoxide has a melting point of 67 ° c . under 0 . 5 mm of hg . the final product is purified by recrystallization in cci 4 . infrared spectrum : bands γnh 2 3340 cm - 1 , γc ═ n 1680 cm - 1 . nmr spectrum in dmso ( d 6 ): 5 . 84 ppm , singlet , 2 protons ( nh 2 ), 4 . 82 - 4 . 38 ppm , complex mass , 1 proton ( h in 5 of the oxazoline ring ); 3 . 77 - 3 ppm , complex mass , 2 protons ( h in 4 of the oxazoline ring ); 3 . 55 ppm , triplet , 4 protons ( ch 2 -- o ); 2 . 58 - 2 . 29 ppm , complex mass , 6 protons ( ch 2 -- n ). synthesis of 2 - amino - 5 -( n - methyl - n - phenylaminomethyl )- 2 - oxazoline . formula i with r 1 = ch 3 , r 2 = c 6 h 5 . this product is synthesized by the method described in example 1 except throughout the reaction between the n - methylaniline and epichlorohydrin the reaction mixture is heated to 50 ° c . the intermediate epoxide has a boiling point of 105 ° c . under 0 . 5 mm of hg . the final product is in the form of an undistillable oil . molecular mass 2 . 5 . infrared spectrum : bands γnh 2 3340 cm - 1 , γc ═ n 1680 cm - 1 . nmr spectrum in dmso ( d 6 ): 7 . 4 - 6 . 4 ppm , complex mass , 5 protons ( h of the aromatic ring ); 5 . 65 ppm , complex mass , 2 protons ( nh 2 ); 4 . 89 - 4 . 44 ppm , 4 - 3 . 05 ppm , complex mass , 4 protons ( ch 2 ); 3 ppm , triplet , 3 protons ( ch 3 ). synthesis of 2 - amino - 5 -( n - benzyl - n - methylaminomethyl )- 2 - oxazoline . formula i with r 1 = ch 2 c 6 h 5 , r 2 = ch 3 . this product is synthesized by the method described in example 1 . the final product is recrystallized in heptane . infrared spectrum : bands γnh 2 3490 cm - 1 , γc ═ n 1680 cm - 1 . nmr spectrum in cdcl 3 : 7 . 22 ppm , singlet , 5 protons ( aromatic h ); 4 . 84 ppm , singlet , 2 protons ( nh 2 ); 4 . 82 - 4 . 48 ppm , complex mass , 1 proton ( h in 5 of oxazoline ring ); 3 . 88 - 3 . 18 ppm , complex mass , 2 protons ( h in 4 of the oxazoline ring ); 3 . 53 ppm , singlet , 2 protons ( benzyl ch 2 ); 2 . 82 - 2 . 17 ppm , complex mass , 2 protons ( ch 2 in 5 on the oxazoline ring ); 2 . 29 ppm , singlet , 3 protons ( nch 3 ). synthesis of 2 - amino -( 4 - methylpiperazinyl )- 5 - methyl - 2 - oxazoline . formula i with r 1 nr 2 = ## str8 ## 0 . 25 mole ( 23 . 13 g ) of epichlorohydrin is added , drop by drop , to a solution of 0 . 25 mole of n - methylpiperazine in 200 cc of ether . the reaction mixture is kept at a temperature below 35 ° c . during the addition ; it is then heated in a double boiler for two hours at the boiling point of the ether . 10 g ( 0 . 25 mole ) of finely powdered soda are added . the precipitate is eliminated by filtering . the ether phase is washed twice with 2 cc of water then dried on na 2 so 4 . the solvent is eliminated and the 1 - methylpiperazinyl - 2 , 3 - epoxypropane is separated by distillation . the purity of this product is checked in infrared by disappearance of the nh band of the starting amine and the appearance of a c -- o -- c band at 930 cm - 1 . 0 . 1 mole ( 6 . 4 g ) of cyanamide monosodium derivative in solution in 100 cc of methanol is added to 0 . 1 mole ( 15 . 6 g ) of n - methyl - 1 - piperazinyl - 2 , 3 - epoxypropane dissolved in 150 cc of methanol . after 15 hours of stirring at ambient temperature the methanol is evaporated and the residue picked up in 200 cc of ethyl ether . the precipitate is eliminated by filerting . the ether phase is quickly washed with 5 cc of water then dried on na 2 so 4 . the ether is evaporated under low pressure . the 2 - amino - n - methyl - 5 - piperazinyll - 2 - oxazoline is collected in the form of an oil that solidifies then is recrystallized in ccl 4 . mp = 130 ° c . yield 61 %. molecular mass 198 . microanalysis : calculated c 9 . 09 %, h 54 . 54 %, n 28 . 28 %; found c 9 . 13 , h 54 . 41 %, n 28 . 19 %. ir spectrum : bands γnh 2 3300 and 3180 cm - 1 , γc ═ n 1680 cm - 1 . nmr of proton in cdl 3 : 2 . 1 - 3 . 0 ppm , 13 protons , complex mass , n n -- ch 2 + ch 3 at 2 . 3 ppm ; 3 . 1 - 4 . 1 ppm , 2 protons , complex mass , oxazoline ch 2 ; 4 . 4 - 5 . 0 ppm , 1 proton , complex mass , cho ; 5 . 4 ppm , 2 protons , wide peak , nh 2 , interchangeable with d 2 o . synthesis of 2 - amino -( 4 - phenylpiperazinyl )- 5 - methyl - 2 - oxazoline . formula i with r 1 nr 2 = ## str9 ## this product is prepared by the method described in example 10 . the intermediate epoxide is obtained in crystallized form . mp = 89 ° c . ; ( recrystallization solvent : heptane ). the final product is purified by recrystallization in heptane . mp = 89 ° c . ; ( recrystallization solvent : heptane ). the final product is purified by recrystallization in heptane . mp = 174 ° c . yield 51 %. molecular mass 260 . microanalysis : calculated c 7 . 69 %, h 64 . 62 %, n 21 . 54 %; found c 7 . 60 %, h 64 . 40 %, n 21 . 34 %. ir spectrum : bands γnh 2 3330 and 3180 cm - 1 , band γc ═ n 1670 cm - 1 . nmr of proton in cdcl 3 : 2 . 3 - 4 . 1 ppm , 12 protons , complex mass , 6 ch 2 ; 4 . 5 - 5 . 0 ppm , 3 protons , complex mass , cho + nh 2 , interchangeable with d 2 o ; 6 . 7 - 7 . 5 ppm , 5 protons , complex mass , aromatic protons . synthesis of 2 - amino -( 4 - benzylpiperidinyl )- 5 - methyl - 2 - oxazoline . formula i with r 1 nr 2 = ## str10 ## this product is synthesized by the method described in example 10 . its yield is 46 %. it is purified by recrystallization in heptane . ir spectrum : bands γnh 2 3320 and 3160 cm - 1 , γc ═ n 1685 cm - 1 . nmr of the proton in cdcl 3 : 1 . 1 - 4 . 1 ppm , 15 protons , complex mass , 7 ch 2 + piperidinic ch ; 4 . 4 - 5 . 0 ppm , 1 proton , complex mass , cho ; 5 . 1 ppm , 2 protons , wide peak , nh 2 , interchangeable with d 2 o ; 6 . 9 - 7 . 4 ppm , 5 protons , complex mass , aromatic protons . synthesis of 2 - amino -( 4 - benzylpiperazinyl )- 5 - methyl - 2 - oxazoline . formula i with r 1 nr 2 = ## str11 ## this product is synthesized as in the method described in example 10 . its yield is 48 %. it is purified by recrystallization in heptane . mp = 96 ° c . molecular mass 274 . microanalysis : calculated c 8 . 03 %, h 65 . 69 %, n 20 . 44 %; found c 8 . 06 %, h 64 . 93 %, n 20 . 34 %. ir spectrum : bands γnh 2 3310 and 3160 cm - 1 , γc ═ n 1680 cm - 1 . nmr of proton in cdcl 3 : 2 . 2 - 3 . 0 ppm , 10 protons , complex mass ## str12 ## 3 . 1 - 4 . 1 ppm , protons , complex mass , benzyl ch 2 + oxazolinic ch 2 : 4 . 4 - 5 . 0 ppm , 3 protons , complex mass , cho + nh 2 interchangeable with d 2 o ; 7 . 2 - 7 . 4 ppm , 8 protons , complex mass , aromatic protons . synthesis of 2 - amino -( 4 - allylpiperazinyl )- 5 - methyl - 2 - oxazoline . formula i with r 1 nh 2 = ## str13 ## this product is synthesized by the method described in example 10 . the intermediate epoxide has a boiling point of 67 ° c . under 1 mb . the final product obtained with a yield of 43 % is purified by recrystallization in heptane . mp = 99 ° c . molecular mass 224 . microanalysis : calculated c 8 . 93 %, h 58 . 93 %, n 25 %, fond c 8 . 93 %, h 58 . 01 %, n 24 . 99 %. ir spectrum : bands γnh 2 3200 and 3160 cm - 1 , γc ═ h 1690 cm - 1 . nmr of the proton in cdcl 3 ; 2 . 2 - 4 . 1 ppm , 14 protons , complex mass , ## str14 ## + oxazoline ch 2 ; 4 . 4 - 6 . 3 ppm , 6 protons , complex mass ; ch 2 = ch --+ cho + nh 2 at 4 . 9 ppm interchangeable with d 2 o . the pharmacological properties of the products of this invention are set forth below . the toxicity was determined in mice for various ways of administraion . table i gives the percentages of mortality as a function of the doses administered . table i______________________________________products percentage of mortality at does ofof orally intraperitoneallyexamples 300 mg / kg 200 mg / kg 200 mg / kg 100 mg / kg______________________________________1 0 02 0 100 03 0 100 04 33 0 100 05 0 100 06 0 07 10010 0 011 0 012 100 0 ( 1 ) 100 013 0 100 014 0 0______________________________________ ( 1 ): 100 mg / kg the product of example 1 shows , after iv administration in mice , an ld 50 of 128 ( 116 - 142 mg / kg ). antihistaminic activity antih 2 was determined in vitro on the right auricle of a guinea pig beating spontaneously . thus , the products of example 1 , 2 , 6 , 13 inibit at more than 50 % at a concentration of 100 microg / ml the chronotropic effect induced by 5 microg / ml of histamine , without exhibiting intrinsic chronotropic effect . the product of example 14 exhibits this activity at a concentration of 50 microg / ml . the positive inotropic activity was determined in vitro on the right auricle of a guinea pig stimulated electrically . the product of example 1 caused , at 100 microg / ml , 100 % increase of the auricle contractile force . the antiallergic activity was determined in rats in the cutaneous passive anaphylaxis test . the animals sensitized by an intradermic injection of ige immediately received , after administration of the product to be tested , an intravenous injection of ovalbumin and evans blue . the products of examples 3 and 4 caused , at 10 mg / kg , 53 and 60 % respectively inhibition of the evans blue spot . the product of example 1 caused 60 % inhibition when it was administered at 100 mg / kg per os . the diuretic activity was determined in rats subjected to a hydric regimen and evaluated by the ratio of sodium excreted in the treated animals to the sodium excreted in control animals . the products of examples 3 and 7 multiplied the sodium excretion by 4 . 2 and 4 . 9 respectively at a dose of 20 mg / kg per os . the hypocholesterolemic activity was determined in mice subjected to a regimen rich in cholesterol and cholic acid for 7 days . after administration per os of the production of example 6 in a dose of 400 mg / kg , a 21 % reduction of cholesterolemia was noted on the 6th and 7th days . this drop in cholesterolemia was accompanied by a 20 % reduction of the hdl - vldl fraction , the hdl / cholesterol ratio being equal to 1 . 01 . the antidepressive psychotropic activities were brought out in the following tests . the products of examples 11 and 12 , administered in an oral dose of 100 mg / kg , potentiated the toxicity of yohimbine . the product of example 11 , administered in 50 mg / kg per os , inhibited ptosis induced by reserpine . the antiinflammatory activity was brought out in the carrageenan edema test in rats . the product of example 11 , administered per os in a dose of 100 mg / kg , caused a 35 % inhibition of carrageenan adema after 4 hours . in a dose of 200 mg / kg administered per os this product is very slightly ulcerigenic . the antihistaminic activity antih 1 was determined in vitro on guinea pig ileum . the products of example 11 and 13 inhibited at more than 80 % the contractions of the guinea pig ileum induced by histamine when they are used in concentrations of 25 and 100 microg / ml respectively . in vitro the product of example 11 caused , in a concentration of 25 microg / ml , 80 % inhibition of the contractions induced by serotinin on guinea pig ileum . the antiulcerigenic activity was shown in the stress ulcer test . the product of example 11 , administered in a dose of 25 mg / kg per os , caused an 88 % inhibition of the stress ulcer in rats . in the model of the spontaneously hypertensive rat , the product of example 13 , administered orally in a dose of 100 mg / kg , caused a drop in systolic pressure of 14 and 15 % respectively after two and four hours . the product of example 14 , administered in a dose of 100 mg / kg under the same conditions , caused a reduction of 21 % of the systolic pressure after six hours . considering their pharmacological activities , joined with a relatively slight toxicity , the products which are the object of this invention can be used in human and animal therapy . thus , when associated with suitable excipients , they can be used in the treatment of depressive states , inflammatory and edematous states , asthma attacks or any condition of allergy , arterial hypertension , gastric hypersecretions , gastroduodenal ulcers . their positive inotropic activity makes it possible to use them in the treatment of acute or chronic cardiac failures . their diuretic properties make it possible to use them in the treatment of edemas and water sodium retentions . their hypolipidemic properties make it possible to use them in hypercholesterolemias and hypertriglyceridemias resistant in the regimen . they will be administered in the form of dragees , tablets , syrup , ampules , rectally as suppositories , intramuscularly or intravenously or topically as ointments or gels . the dose will vary , depending on the indication and patient , from 1 to 100 mg / d in 2 to 6 doses orally , 1 to 100 mg / d in 1 or 2 doses rectally , from 0 . 5 to 50 mg parenterally . they can also be used for inhalation , for example , as sprays . obviously , numerous modifications and variations of the present invention are possible in light of the above teachings . it is therefore to be understood that within the scope of the appended claims , the invention may be practiced otherwise than as specifically described herein .